双鹭药业(002038) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was ¥440,127,601.59, representing a 94.31% increase compared to ¥226,512,271.34 in the same period last year[9] - Net profit attributable to shareholders was ¥182,362,771.17, up 43.48% from ¥127,101,509.93 year-on-year[9] - The net profit after deducting non-recurring gains and losses was ¥171,921,150.14, reflecting a 63.63% increase from ¥105,070,177.57 in the previous year[9] - Basic earnings per share were ¥0.2663, up 43.48% from ¥0.1856 in the previous year[9] - The net profit attributable to shareholders for the first half of 2018 is expected to increase by 35.00% to 65.00%, ranging from ¥314,232,380.63 to ¥384,061,798.54 compared to ¥232,764,726.39 in the same period of 2017[18] - Operating revenue increased by 94.31% year-on-year, primarily due to changes in sales models, increased product sales, and the launch of new products[18] - The total comprehensive income for Q1 2018 was CNY 179,653,256.35, an increase from CNY 127,157,179.20 in Q1 2017, representing a growth of approximately 41%[42] Cash Flow - The net cash flow from operating activities reached ¥155,814,084.75, an increase of 83.86% compared to ¥84,745,825.37 in the same period last year[9] - The net cash flow from operating activities for the current period is ¥160,994,554.43, an increase of 83.5% compared to ¥87,642,389.69 in the previous period[49] - Total cash inflow from operating activities is ¥498,628,956.13, significantly higher than ¥279,816,062.67 in the previous period[49] - The total cash inflow from operating activities was CNY 505,742,572.55, compared to CNY 287,630,187.69 in the previous year, reflecting an increase of about 76%[45] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,759,508,578.60, a 3.80% increase from ¥4,585,061,501.49 at the end of the previous year[9] - The total assets of the company as of March 31, 2018, amounted to ¥4,759,508,578.60, compared to ¥4,585,061,501.49 at the beginning of the year[30] - The total liabilities decreased slightly to CNY 282.18 million from CNY 285.67 million, a reduction of 1.7%[32] - The balance of accounts receivable at the end of the reporting period was ¥606,269,467.42, up from ¥591,472,969.23 at the beginning[29] Shareholder Information - Net assets attributable to shareholders increased by 4.20% to ¥4,449,900,131.24 from ¥4,270,639,327.26 at the end of the previous year[9] - The total number of ordinary shareholders at the end of the reporting period was 32,762[13] - The total equity attributable to shareholders of the parent company reached CNY 4.45 billion, up from CNY 4.27 billion, representing an increase of 4.2%[32] Expenses - Sales expenses surged by 475.22% year-on-year, attributed to changes in sales strategies and an increase in direct sales channels and personnel[18] - Operating costs for the same period amounted to CNY 242.74 million, up from CNY 111.05 million, indicating a year-over-year increase of 118.3%[37] - The company's tax expenses increased by 50.37% year-on-year, corresponding to the rise in profits[18] - The company reported a significant increase in sales expenses, which rose to CNY 136.08 million from CNY 23.66 million, a staggering increase of 474.5%[38] Government Support - The company received government subsidies amounting to ¥2,987,095.13 during the reporting period[10] Audit and Reporting - The company did not undergo an audit for the first quarter report[51] - The report was presented by Chairman Xu Mingbo on April 25, 2018[52]